Daiichi Sankyo Co Ltd
Company Profile
Business description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Contact
3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo103-8426
JPNT: +81 362251111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2025
Employees
18,726
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,166.70 | 8.80 | 0.11% |
| CAC 40 | 8,134.60 | 112.27 | 1.40% |
| DAX 40 | 23,152.17 | 299.51 | 1.31% |
| Dow JONES (US) | 42,583.32 | 597.97 | 1.42% |
| FTSE 100 | 8,701.74 | 63.73 | 0.74% |
| HKSE | 23,344.25 | 561.31 | -2.35% |
| NASDAQ | 18,188.59 | 404.54 | 2.27% |
| Nikkei 225 | 37,780.54 | 172.05 | 0.46% |
| NZX 50 Index | 12,184.51 | 56.30 | 0.46% |
| S&P 500 | 5,767.57 | 100.01 | 1.76% |
| S&P/ASX 200 | 7,942.50 | 5.60 | 0.07% |
| SSE Composite Index | 3,369.98 | 0.05 | -0.00% |